Last reviewed · How we verify
Tetracyclin ointment
Tetracyclin ointment is a Tetracycline antibiotic Small molecule drug developed by University of Oslo. It is currently FDA-approved for Topical treatment of bacterial skin infections, Wound infection prevention, Superficial skin and soft tissue infections. Also known as: Amoxicillin, Esomeprazole, Bismuth, marsupialization procedure.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation and bacterial growth.
Tetracyclin ointment has been studied as a treatment for post-operative wound infection. The exact mechanism of action of tetracyclin ointment is unknown.
At a glance
| Generic name | Tetracyclin ointment |
|---|---|
| Also known as | Amoxicillin, Esomeprazole, Bismuth, marsupialization procedure |
| Sponsor | University of Oslo |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Tetracyclines are broad-spectrum antibiotics that work by reversibly binding to the bacterial 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosome. This inhibits protein synthesis and leads to bacteriostatic effects against a wide range of gram-positive and gram-negative bacteria. When formulated as an ointment, tetracycline is applied topically to treat localized bacterial skin infections and prevent infection in wounds.
Approved indications
- Topical treatment of bacterial skin infections
- Wound infection prevention
- Superficial skin and soft tissue infections
Common side effects
- Local skin irritation
- Contact dermatitis
- Photosensitivity (systemic form)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetracyclin ointment CI brief — competitive landscape report
- Tetracyclin ointment updates RSS · CI watch RSS
- University of Oslo portfolio CI
Frequently asked questions about Tetracyclin ointment
What is Tetracyclin ointment?
How does Tetracyclin ointment work?
What is Tetracyclin ointment used for?
Who makes Tetracyclin ointment?
Is Tetracyclin ointment also known as anything else?
What drug class is Tetracyclin ointment in?
What development phase is Tetracyclin ointment in?
What are the side effects of Tetracyclin ointment?
What does Tetracyclin ointment target?
Related
- Drug class: All Tetracycline antibiotic drugs
- Target: All drugs targeting Bacterial 30S ribosomal subunit
- Manufacturer: University of Oslo — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Dermatology
- Indication: Drugs for Topical treatment of bacterial skin infections
- Indication: Drugs for Wound infection prevention
- Indication: Drugs for Superficial skin and soft tissue infections
- Also known as: Amoxicillin, Esomeprazole, Bismuth, marsupialization procedure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing